These data correlate with the results of a study by Shukla et al. (2016), where a cohort of 355 patients was studied and using Cox regression analysis revealed that PCa patients with high PCAT-14 expression have better outcomes and are significantly associated with better prostate cancer specific survival (PSS), metastasis free survival (MFS), biochemical relapse-free survival (BRFS), with borderline significance for OS [92]. The gene discussed is PCAT14; the disease is prostate cancer.